Galectin Therapeutics Inc
PHPN
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Oracle’s cloud database business is riding the AI wave.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,057.60 | 48.70 | -0.53% |
CAC 40 | 7,857.98 | 14.04 | -0.18% |
DAX 40 | 23,589.14 | 22.19 | -0.09% |
Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
FTSE 100 | 9,202.92 | 20.40 | -0.22% |
HKSE | 26,518.65 | 359.53 | 1.37% |
NASDAQ | 22,573.47 | 215.50 | -0.95% |
Nikkei 225 | 45,630.31 | 136.65 | 0.30% |
NZX 50 Index | 13,181.31 | 44.77 | 0.34% |
S&P 500 | 6,656.92 | 36.83 | -0.55% |
S&P/ASX 200 | 8,764.50 | 50.50 | -0.57% |
SSE Composite Index | 3,853.64 | 31.81 | 0.83% |